The concept of personalized medicine has got its credential due to the development of molecular techniques. It involves right drug & dose, right patient and with right time administration of a medication. By averting the knowledge of gene sequence and their functions, biomedical researches are diversified towards inter-individual variations that are expected to become an eminent part of treatment planning in terms of efficacy and toxic side effects of drugs. The clairvoyance of the future health care adjudicate a system in which patient care is consistently belay by captivating information on the individual patient's genomes and their downstream products. By combining the credentials of various disciplines such as life sciences, mathematics, physics, chemistry, and information and communication technology ameliorated this concept.
doctrine of personalized medicine. This is becoming possible thanks to the latest diagnostic tools that utilize molecular biology techniques to analyze genomes of bacteria or human being. Since last few years our knowledge on the genetic background of individual receptiveness toward drugs has progressed efficiently. Once drug effect on people"s genes which shows small variations or changes in their nucleotide (DNA base) content, can be ascertained by genetic testing the way become more easy. Rosenberg [4] robust evaluation and sensible regulation of genetic tests are necessary to realize the promise of personalized medicine. This includes consideration of a drug and/or treatment"s efficacy, and genetic test"s analytical and clinical validity, in order to ensure that the test is safe, and performs as intended.
Pharmacogenomics (PG) studies exhibit how genotypic variation is responsible for variability in drug response and applies concepts about variations in hepatic drug metabolism enzymes to the rest of genome. Although environment, diet, age, lifestyle, and state of health all can influence a person's response to drugs, understanding an individual's genetic profile is thought to be the key to creating personalized drugs with greater efficacy and safety. The terms pharmacogenetics and pharmacogenomics are often used interchangeably, which causes some confusion. However, the term pharmacogenomics is preferred when referring to clinical practice [5] .
HISTORICAL ASPECTS AND "-OMICS" TECHNOLOGY
Genomics is a discipline in genetics concerning the study of the genomes of organisms. It mainly determine the entire DNA sequence of organisms (genetic mapping). Fred Sanger and coworkers (in 1970-1980s) have first sequenced a genome of virus. They also invented the techniques of sequencing, genome mapping, data storage, and bioinformatic analyses. Chavda and Gohil [6] quoted that the genetic variations were first studied in relation to ABO blood group frequencies at the end of First World War by two Polish scientists Ludwik and HankaHirszfeld. Polymorphisms or SNPs (pronounced "snips") are DNA sequence variations that occur when a single nucleotide (A, T, C, or G) is altered in the genomic DNA sequence. Two of every three SNPs involve the replacement of cytosine (C) with thymine (T). SNPs can occur in both coding (exons) and non-coding (introns) regions of the genome. Although many SNPs have no effect on cell function, certain others could predispose people to disease or influence their response to a drug. [7] attention now days. Study of the full set of proteins in a cell type or tissue, and the changes during various conditions, is called proteomics. On the other hand materiomics is defined as the study of the material properties of biological materials. It also considers their effect on the macroscopic function and failure in their biological context, linking processes, structure and properties at multiple scales through a materials science approach. Each cell of our body is capable of making complete human being. However, not all the genes are expressed in all the cells. That"s why proteomic is very much specific in its finding either a bio-marker or in functional therapeutics. PROTEOMEX is representing a combination of proteomics and serology which is most widely used in the biomarker"s discovery. The proteome is dynamic in nature unlike genome which depends on the tissue, cell type and environmental factors. Thus, genomic approaches alone are insufficient to investigate the causative mechanism underlying disease. Chavda and Gohil [6] cited that the current version of human gene catalogue contains 22,287 gene loci with a total of 34,214 transcripts. Over 1.4 million SNPs have been identified so far and the number is increasing every day as more humans are being studied. where the drug causes toxicity leading to SARs. In short for scientific, economic, and social point of view suggest that "tailor-made" medicine is future medicine for diagnosis and therapeutics.
Personalised medicine is defined as: "the capacity to predict disease development and influence decisions about lifestyle choices or to tailor medical practice to an individual" [8] .
BIOMARKERS
For predicting likely course of illness and to check any progress of an illness in a given patient biomarkers are used which also sense individual response to treatment. In medical terminology, a biomarker can be a traceable substance that is introduced into an organism as a means to examine organ function or other aspects of health. Małyska and Twardowski [9] reported a useful way of finding genetic causes for diseases such as schizophrenia has been the use of a special kind of biomarker called an endopheno type. The genomic biomarkers (GBMs) for diagnosis of specific diseases have showing steep growth since last few year. Slamon [10] and coworkers defined them as to be diagnostic, prognostic or predictive markers. The enzymes and hormones linked with tumors are of prior importance as biomarkers when it comes to oncology as routine biochemical techniques detect them easily. Their presence is not always indicative of the presence of a specific tumor. For example, an increase in the levels of the prostate-specific antigen (PSA) indicates a high likelihood of a prostate tumor being present, but it can also be a result of a mild hyperplasia. Similarly, raised levels of the carcinoembryonic antigen (CEA) are characteristic in between 60-90% of colon cancer cases and 50-80% of pancreatic cancers. A prognostic marker can be defined as either a single trait or signature of traits that separates different populations with respect to the risk of an outcome of interest in absence of treatment, or despite non-targeted 'standard' treatment. Prognostic markers are useful to assess the risk of disease recurrence, by comparing the outcome for marker-positive and marker-negative patients, regardless of the treatment, where intervention (e.g., drug therapy) is not a variable. Predictive markers can be defined as a single trait or signature of traits that separate different populations with respect to the outcome of interest in response to a particular targeted treatment. According to Kondratovich and Mansfield [11] genomics, Transcriptomics, Proteomics and Metabolomics are some of the techniques which are utilized in the screening of biomarkers. The biomarkers are classified in to three classes:
DNA Biomarker
Mutations in oncogenes, tumor suppressor genes, and mismatch-repair genes can serve as DNA biomarkers. Promoter region methylation of MGMT, an enzyme that reverses 5'-guanine alkylation, predicts the response or resistance of tumors to nitrosourea alkylating agents. [12] 2. RNA Biomarker RNA biomarkers include differences in the transcription levels, or RNA molecules that take part in regulation. Pattern based RNA expression analysis of clinical breast cancers has identified previously unknown molecular subtypes. [12, 13] .
Protein Biomarker
Not protein quantity, but its function can be utilized as a marker. Single RNA markers in tumor classification, prognosis or prediction of response to therapy, protein-based "fingerprints" may outperform individual protein markers. [12, 13] © 2016 Asian Medical Journals. All Rights Reserved. 
THERAPEUTICS
Genetic susceptibility to complex diseases and genetic variability in drug responses were comprehensively studied particular after the completion of the Human Genome Project. Lander, et al. [24] reported that pharmacogenomics findings in last decades or so allow bold steps to be taken toward personalized medicine. Genomics has become an integral part of modern drug development, and a large number of pharmaceutical companies are using this information to identify novel drug targets, identify patient subpopulations that are likely to benefit from the therapy under development, or for other screening purposes. Hong-Guang and Felix [25] reported that the safety and efficacy of a drug is evaluated according to strict regulatory guidelines before the drug is marketed. However, it is impossible for an approved drug to be safe or effective for everyone. Genetic and environmental factors, including their interactions, result in substantial variability among individuals. Drug safety varies from drug to drug, from person to person, and even from disease to disease. The costs of drug-related morbidity and mortality are expected to exceed US$177 billion annually in the USA alone. As per Ernst and Grizzle [26] many drugs have been withdrawn from the major markets only because they cause severe toxicity in a small number of people. The thiopurine drugs, azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG), are widely used for childhood acute lymphoblastic leukemia (ALL), organ transplant rejection, and rheumatic diseases. Prospective genotyping or phenotyping is able to improve thiopurine S-methyltransferase associated drug therapy and avoid drug toxicity.
Gardiner [27] quoted that the US Food & Drug Administration (FDA) has updated the labels of 6-MP and AZA to inform consumers about the risk of toxicity, and recommends genotyping before the initiation of treatment with these drugs. An individual patient"s genetic factors, including gene-gene and allele-allele interactions are responsible for wide variation in warfarin dose requirements, accounting for approximately 75-85% of the overall variability. Veenstra, et al. [28] studied SCN1A IVS5-91 G allele and IVS5-91G allele were linked to significantly reduced maximum carbamazepine and phenytoin doses respectively. Tate, et al. [29] studied that in CYP2D6 poor metabolizers shows reduced analgesics activity of codeine where in ultra-rapid metabolizer increased response to normal doses, or, in some cases, severe toxicity as per Gasche, et al. [30] . Tyrosine kinase inhibitors; Gefitinib (Iressa®) and erlotinib (Tarceva®) were successfully utilized in the treatment of adenocarcinomas of the bronchioloalveclar carcinoma (BAC) subtype. The human epidermal growth factor receptor (HER)2 (ErbB2) gene is amplified in up to 30% of patients with breast cancer, resulting in the overexpression of the HER2 receptor protein that serves as the target for the anti-HER2 antibody trastuzumab (Herceptin®), a humanized monoclonal antibody while cetuximab (Erbitux®) binds to the extracellular domain of EGFR. Slamon, et al. [31] studied that chronic myeloid leukemia has been a target for Imatinib (Gleevec®) is a competitive inhibitor of ATP binding to the ABL kinase. Druker, et al. [32] reported that if we talk abount recent progress, Vemurafenib is a B-Raf enzyme inhibitor developed by Plexxikon and Genentech for the treatment of late-stage melanoma [33] .
ISSUES AND CHALLENGES
On 
Ethical Issues
Privacy of the study subjects is one of the most cardinal issue when one talks about personalized care. Lindpainter [35] mentioned in their work that each participants should be adequately informed that how their genetic material will be handled, what all tests may be done, how and by whom the data will be utilized, where the genetic material be stored and how secure the DNA blanks are? As per Bansal, et al. [34] DNA may be required for future use and how that data will be maintained. Informed consent for future use should also be taken before hand.
Patent"s family should be informed or not, is one point to be addressed further [36] .
Legal Issues
Before full implementations of any diagnostic or therapeutic intervention being made for personalized care this surely be addressed cogently; Bansal, et al. [34] . Lindpainter [35] quoted some important questions regarding personalized care. What is the legal liability if that data if stolen or lost or made public? Who is responsible for the damages? What is the compensation?
What is legal issue if discrimination is made by job providers or insurance firms? In case the job providers know the person"s gene data and avoids job which is good for company as only best fitted individuals will be there to improve success but a loss for person who may have to face unemployment and switch over to malpractices, or insurance cover is avoided [36] .
Social Issues
It is well castigated if any new diagnostic method or therapy invented using the -omics technology leads to increase in therapeutics cost. Bansal, et al. [34] have well defined this problem in their work. Patient becomes the main aim but of course! This leads to breach in privacy of whole community whose consent is not taken. This may also lead to formation of a group susceptible to a particular drug, having a possibility of a particular disease in future or having a predisposition to something not curable as per current standard [35, 36 ].
PHARMACOGENOMICS TESTING IN CHILDREN
It is quiet tough to conquer such issues especially ethical one however it may be done for conditions where immediate therapeutic outcome may be feasible as per current levels of advances in pharmacology. Etical issues needs consideration of complete genome matching even though the final decision will be made by the patient only. Anticancer therapy to a patient deficient to Thiopurine S Methyl Transferase after math in myelosuppression. Such patients can be advised to undergo pharmacogenomics testing so as to predict outcome and alternatives [34] .
BARRIERS TO PROGRESS IN PERSONALIZED CARE
As mentioned earlier in this manuscript that the -omics technologies are in emerging phase and have to pass many barrier before it actually commercialized. with gene knowledge so as to tackle any problem during therapy as it is patient specific. 
CONCLUSION
Due to the advancement in so called "-omics" technology the concept of personalized medicine has become reality. The identification of SNPs from almost three billion base long
